Slingshot members are tracking this event:

Gilead (GILD) Plans to Submit FDA Application for Sofosbuvir/Velpatasvir/Voxilaprevir in Treatment-Experienced Genotype 1-6 Chronic HCV-Infected Patients by End of 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Fda, Regulatory Application, Sofosbuvir, Velpatasvir, Voxilaprevir, Triple Combo Pill, Treatment-experienced, Genotype 1-6, Chronic Hcv